Kiora Pharmaceuticals Licensing Deal with Senju Pharmaceutical Co., Ltd. Worth $3.5M
Kiora Pharmaceuticals entered into an exclusive license agreement with Senju Pharmaceutical to develop and commercialize KIO-401, a late-stage oral small-molecule calpain inhibitor for ophthalmic diseases, in all territories outside of Asia. Kiora will pay an upfront fee of $3.5 million, low teen millions upon technology transfer, and up to $168.5 million in potential regulatory and commercial milestones, plus single-digit royalties.
- Value
- $3.5M
- Counterparty
- Senju Pharmaceutical Co., Ltd.